Meeting
2017 Gastrointestinal Cancers Symposium
Modified FOLFIRINOX for metastatic pancreatic adenocarcinoma after failure of nab-paclitaxel plus gemcitabine.
Authors
Masato Ozaka
Department of Gastroenterology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan
Masato Ozaka , Takashi Sasaki , Seita Kataoka , Ryo Kanata , Kazunaga Ishigaki , Ikuhiro Yamada , Masato Matsuyama , Koichi Takano , Naoki Sasahira
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 467)
DOI
10.1200/JCO.2017.35.4_suppl.467
Abstract #
467
Poster Bd #
M7
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Second-line treatment of modified FOLFIRINOX or nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma.
First Author: Masato Ozaka
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Real-world overall survival and time to next treatment in patients with metastatic pancreatic ductal adenocarcinoma who received FOLFIRINOX and modified FOLFIRINOX in the first line.
First Author: Syvart Dennen
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Metronomic oral cyclophosphamide as maintenance therapy in metastatic pancreatic ductal adenocarcinoma.
First Author: Michele Reni
Poster
2022 ASCO Annual Meeting
Phase 3, multicenter, randomized study of CPI-613 with modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) as first-line therapy for patients with metastatic adenocarcinoma of the pancreas (AVENGER500).
First Author: Philip Agop Philip